Literature DB >> 27894205

Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013.

Anna Asklid1,2, Maria Winqvist1,3, Sandra Eketorp Sylvan1, Agnes Mattsson1,4, Einar Björgvinsson1,2, Frans Søltoft5, Johanna Repits6, Joris Diels7, Anders Österborg1,3, Lotta Hansson1,3.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27894205     DOI: 10.1080/10428194.2016.1246727

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center.

Authors:  Juha Ranti; Katariina Perkonoja; Tommi Kauko; Heidi Loponen; Emmi I Joensuu; Tiina M Järvinen
Journal:  EJHaem       Date:  2021-11-21

2.  First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.

Authors:  Sandra Eketorp Sylvan; Anna Asklid; Hemming Johansson; Jenny Klintman; Jenny Bjellvi; Staffan Tolvgård; Eva Kimby; Stefan Norin; Per-Ola Andersson; Claes Karlsson; Karin Karlsson; Birgitta Lauri; Mattias Mattsson; Anna Bergendahl Sandstedt; Maria Strandberg; Anders Österborg; Lotta Hansson
Journal:  Haematologica       Date:  2018-11-22       Impact factor: 9.941

3.  Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005-2015 show improved survival over time.

Authors:  Vesa Lindström; Katja M Hakkarainen; Juha Mehtälä; Riho Klement; Amy Leval; Tiina M Järvinen
Journal:  Eur J Haematol       Date:  2019-07-25       Impact factor: 2.997

4.  Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.

Authors:  Lotta Hansson; Anna Asklid; Joris Diels; Sandra Eketorp-Sylvan; Johanna Repits; Frans Søltoft; Ulrich Jäger; Anders Österborg
Journal:  Ann Hematol       Date:  2017-07-31       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.